The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study
Anthony W Solomon, Alexandre L Pavluck, Paul Courtright, Agatha Aboe, Liknaw Adamu, Wondu Alemayehu, Menbere Alemu, Neal DE Alexander, Amir Bedri Kello, Berhanu Bero, Simon J Brooker, Brian K Chu, Michael Dejene, Paul M Emerson, Rebecca M Flueckiger, Solomon Gadisa, Katherine Gass, Teshome Gebre, Zelalem Habtamu, Erik Harvey Show all
OPHTHALMIC EPIDEMIOLOGY | TAYLOR & FRANCIS INC | Published : 2015
PURPOSE: To complete the baseline trachoma map worldwide by conducting population-based surveys in an estimated 1238 suspected endemic districts of 34 countries. METHODS: A series of national and sub-national projects owned, managed and staffed by ministries of health, conduct house-to-house cluster random sample surveys in evaluation units, which generally correspond to "health district" size: populations of 100,000-250,000 people. In each evaluation unit, we invite all residents aged 1 year and older from h households in each of c clusters to be examined for clinical signs of trachoma, where h is the number of households that can be seen by 1 team in 1 day, and the product h × c is calcula..View full abstract
Awarded by United Kingdom's Department for International Development (DFID)
Awarded by United States Agency for International Development through its END in Asia grant
Awarded by Medical Research Council
The GTMP is funded by a grant from the United Kingdom's Department for International Development (DFID)(ARIES: 203145) to Sightsavers, who is leading a consortium of non-governmental organizations and academic institutions to complete the work described. Additional funding for fieldwork is provided by the United States Agency for International Development through its END in Asia grant to FHI 360; and its ENVISION grant to Sightsavers. The Committee established in March 2012 to examine issues surrounding completion of global trachoma mapping was initially supported by the International Trachoma Initiative, who receive funding from Pfizer. AWS was a Wellcome Trust Intermediate Clinical Fellow (098521) and SJB a Wellcome Trust Senior Research Fellow (098045) at the London School of Hygiene & Tropical Medicine. None of the funders had any role in study design, in study implementation or analysis or interpretation of data, in the decisions on where, how or when to publish in the peer reviewed press, or in preparation of the manuscript.